Anti-Hu CD13 Purified Low Endotoxin

Anti-Hu CD13 Purified Low Endotoxin
Regulatory status
RUO
Antigen
CD13
Clone
WM15
Format
Purified Low Endotoxin
Reactivity
Human, Non-human primates
Application
IP, FC (QC tested), IHC(F), FUNC
Variant
0.1 mg
12-396-C100
In stock
Variant
0.1 mg
11-261-C100
In stock
Product details
References
Isotype
Mouse IgG1
Specificity
The antibody WM15 recognises an extracellular epitope of human CD13 cell surface glycoprotein, a 150 kDa molecule expressed on granulocytes, endothelial cells, epithelial cells and myeloid progenitors.
Workshop
HLDA III: WS Code M 213; HLDA IV: WS Code M 44; HLDA IV: WS Code M 209; HLDA V: WS Code M MA191
Application
IP, FC (QC tested), IHC(F), FUNC
Reactivity
Human, Non-human primates
Immunogen
Human AML cells
Other names
Aminopeptidase N, APN, PEPN, ANPEP, gp150, LAP1
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography
Formulation
Low endotoxin azide free phosphate buffered saline (PBS) solution, 0.2 μm filter sterilized. Endotoxin level is less than 0.01 EU/μg of the protein, as determined by the LAL test.
Storage and handling
Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Exbio licence note
Unless indicated otherwise, all products are For Research Use Only and not for diagnostic use. In vivo diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s. © 2019 EXBIO Praha, a.s. All rights reserved.

General references:

Tokuhara T, Hattori N, Ishida H, Hirai T, Higashiyama M, Kodama K, Miyake M. Clinical significance of aminopeptidase N in non-small cell lung cancer. Clin Cancer Res. 2006 Jul 1;12(13):3971-8.
PubMed
Petrovic N, Schacke W, Gahagan JR, O'Conor CA, Winnicka B, Conway RE, Mina-Osorio P, Shapiro LH. CD13/APN regulates endothelial invasion and filopodia formation. Blood. 2007 Jul 1;110(1):142-50.
PubMed
Terauchi M, Kajiyama H, Shibata K, Ino K, Nawa A, Mizutani S, Kikkawa F. Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells. BMC Cancer. 2007 Jul 27;7:140.
PubMed

Product specific references:

Favaloro EJ, Browning T, Facey D: CD13 (GP150; aminopeptidase-N): predominant functional activity in blood is localized to plasma and is not cell-surface associated. Exp Hematol. 1993 Dec;21(13):1695-701.
PubMed
McCormack E, Mujic M, Osdal T, Bruserud O, Gjertsen BT: Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia. Blood. 2013 Feb 14;121(7):e34-42. doi: 10.1182/blood-2012-05-429555.
PubMed
Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995).
Leukocyte Typing IV., Knapp W. et al. (Eds.), Oxford University Press (1989).
Leukocyte Typing III., McMichael A.J. et al. (Eds.), Oxford University Press (1987).
Bradstock KF, Favaloro EJ, Kabral A, Kerr A, Hughes WG, Musgrove E: Myeloid progenitor surface antigen identified by monoclonal antibody. Br J Haematol. 1985 Sep;61(1):11-20.
PubMed
Bradstock KF, Favaloro EJ, Kabral A, Kerr A, Hughes WG, Berndt MC, Musgrove E: Human myeloid differentiation antigens identified by monoclonal antibodies: expression on leukemic cells. Pathology. 1985 Jul;17(3):392-9.
PubMed
Variant
0.1 mg
12-396-C100
In stock
Variant
0.1 mg
11-261-C100
In stock